Patent application number | Description | Published |
20090131683 | Process for the preparation of atorvastatin and intermediates - A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising:
| 05-21-2009 |
20110065931 | ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATES - Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications. | 03-17-2011 |
20120065409 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF - There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds. (I) | 03-15-2012 |
20130274474 | 1,3-OXATHIOLANE DERIVATIVES, PROCESS FOR THE PREPARATION OF 1,3-OXATHIOLANE DERIVATIVES AND INTERMEDIATES THEREOF - This invention relates to 1,3-oxathiolane derivatives (I), processes for the preparation of 1,3-oxathiolane derivatives and intermediate compounds thereof. | 10-17-2013 |
20150175583 | FORMS OF VILAZODONE AND PROCESSES FOR THE PREPARATION THEREOF - Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof. | 06-25-2015 |
20150252000 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES - This invention provides processes for preparation of 3-alkyl indoles of Formula 1: wherein A | 09-10-2015 |
20150274699 | SOLID FORMS OF NILOTINIB HYDROCHLORIDE - Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML). | 10-01-2015 |
20150284407 | POLYMORPHIC FORMS OF RIFAXIMIN - Provided for in the instant application are two additional forms of rifaximin, namely rifaximin polymorphic forms APO-III and APO-IV. Also provided are allegedly novel processes for preparing the previously disclosed rifaximin polymorphic forms APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery. | 10-08-2015 |